Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
96 studies found for:    Open Studies | niaid
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | niaid
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Not yet recruiting Targeted Microbiome Transplant in Atopic Dermatitis
Condition: Atopic Dermatitis (AD)
Interventions: Biological: TMT Lotion;   Drug: Placebo Lotion
2 Not yet recruiting Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB
Conditions: Tuberculosis;   HIV Infections
Interventions: Drug: Delamanid;   Drug: Optimized multidrug background regimen (OBR) for children with MDR-TB
3 Not yet recruiting Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®-or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV (vCP2438);   Biological: Bivalent subtype C gp120/MF59;   Biological: Bivalent subtype C gp120/AS01(B);   Biological: Placebo
4 Recruiting Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: D46/NS2/N/ΔM2-2-HindIII;   Biological: Placebo
5 Recruiting Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants and Children 6 to 24 Months of Age
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV D46/NS2/N/ΔM2-2-HindIII Vaccine;   Biological: Placebo
6 Not yet recruiting JBT-101 in Systemic Lupus Erythematosus (SLE)
Conditions: Systemic Lupus Erythematosus;   SLE;   Lupus
Interventions: Drug: JBT-101;   Drug: Placebo
7 Not yet recruiting Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants
Condition: HIV Infections
Interventions: Drug: Dolutegravir;   Drug: Emtricitabine/tenofovir alafenamide;   Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Efavirenz/emtricitabine/tenofovir disoproxil fumarate
8 Recruiting Etiology of Eczema Herpeticum (EH)
Condition: Eczema Herpeticum
Intervention:
9 Recruiting Safety and Immune Response to a Clade C DNA HIV Vaccine
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine;   Biological: Protein/MF59 vaccine;   Biological: Placebo
10 Recruiting Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV (vCP2438);   Biological: Bivalent Subtype C gp120/MF59;   Biological: Placebo
11 Recruiting Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant
Condition: Influenza A Virus, H7N9 Subtype
Interventions: Biological: H7N9 pLAIV;   Biological: H7N9 pIIV;   Biological: AS03 adjuvant
12 Not yet recruiting Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus
Condition: Influenza, Human
Interventions: Biological: Seasonal LAIV;   Biological: Placebo;   Biological: Wild-type A/California/2009-like Influenza Virus
13 Recruiting Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine;   Biological: Bivalent Subtype C gp120/MF59 vaccine;   Biological: Bivalent Subtype C gp120/AS01B vaccine;   Biological: Placebo
14 Not yet recruiting Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in HIV-Infected and HIV-Uninfected Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis
Conditions: Tuberculosis;   HIV Infections
Intervention: Drug: Bedaquiline
15 Not yet recruiting Novel Mobile Device Application to Improve Adherence
Conditions: Pediatric Heart Transplant Recipients;   Pediatric Cardiac Transplantation;   Pediatric Heart Transplantation
Interventions: Device: TPP;   Other: Control Group
16 Recruiting Post‐Traumatic Stress Symptoms (PTSS) in Transplant Recipients
Conditions: Solid Organ Transplant Recipients;   Parent(s)/Guardian of Referenced Transplant Recipients
Intervention: Other: Assessment of adherence, mental health, behavioral, quality of life and biological constructs
17 Not yet recruiting Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease
Condition: Influenza
Interventions: Biological: H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV);   Biological: H3N2v inactivated subvirion influenza vaccine;   Biological: Placebo
18 Recruiting Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age
Condition: Dengue
Interventions: Biological: TetraVax-DV TV005;   Biological: Placebo
19 Recruiting Partnership for Research on Ebola VACcinations
Condition: Ebola Virus Disease
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: rVSVΔG-ZEBOV-GP;   Biological: Placebo;   Biological: rVSV boost
20 Recruiting Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30
Condition: Dengue
Interventions: Biological: TetraVax-DV-TV005;   Biological: rDEN3Δ30;   Biological: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.